All the cancer cell lines used in the study are known to overexpress wt-EGFR with a high basal level of phosphorylation, but their corresponding cancers are intrinsically resistant to TKIs in clinic [9,53,54,55,56]. This evidence concerns the gene EGFR and cancer.